Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from CASI Pharmaceuticals ( (CASI) ).
On February 20, 2026, CASI Pharmaceuticals announced it had closed the third tranche of its previously arranged US$20 million convertible note financing with ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He. The latest issuance consists of a US$5 million convertible note maturing in 36 months with a 12% annual interest rate and defined conversion terms into ordinary shares, providing additional funding flexibility while potentially diluting equity depending on future share prices.
Under the terms, CASI may convert the note into ordinary shares at maturity based on the five-day volume weighted average closing price preceding that date, while the investor can elect to convert from the 91st day after issuance through maturity on similar pricing mechanics. The conversion price is capped between US$1 and US$2 per share, a structure that balances the company’s need for capital with downside protection for the investor and could influence CASI’s capital structure and shareholder base as the note approaches conversion or repayment.
The most recent analyst rating on (CASI) stock is a Hold with a $0.96 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
The score is primarily weighed down by poor financial performance (declining revenue, ongoing losses, negative and worsening free cash flow, and very high leverage). Technicals are somewhat improved in the short term but remain weak versus longer-term trend levels, while valuation is difficult to support due to negative earnings and no dividend yield data.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company listed on Nasdaq and headquartered in Beijing, China. The company is focused on developing CID-103, an anti-CD38 monoclonal antibody targeting patients with organ transplant rejection and autoimmune diseases, positioning it within the immunology and specialty biologics segment of the healthcare market.
Average Trading Volume: 37,228
Technical Sentiment Signal: Sell
Current Market Cap: $12.07M
For an in-depth examination of CASI stock, go to TipRanks’ Overview page.